FDA-approved therapies for PsA or RA
| Class | Available agent | Indication | |
| PsA | RA | ||
| Conventional synthetic DMARDs | |||
| Methotrexate | * | ✓ | |
| Leflunomide | — | ✓ | |
| Corticosteroids | ✓† | ✓ | |
| Hydroxychloroquine | — | ✓ | |
| Sulfasalazine | * | ✓ | |
| Ciclosporin | * | ✓‡ | |
| Biological DMARDs | |||
| TNF-α inhibitors | Etanercept | ✓ | ✓ |
| Infliximab | ✓ | ✓ | |
| Adalimumab | ✓ | ✓ | |
| Golimumab | ✓ | ✓ | |
| Certolizumab pegol | ✓ | ✓ | |
| IL-17A inhibitor | Secukinumab | ✓ | – |
| Ixekizumab | ✓ | – | |
| IL-12/23 inhibitor | Ustekinumab | ✓ | – |
| IL-6 receptor inhibitors | Tocilizumab | – | ✓ |
| Sarilumab | – | ✓ | |
| IL-1 receptor antagonist | Anakinra | – | ✓ |
| T-cell activation inhibitor | Abatacept | ✓ | ✓ |
| CD20 inhibitor | Rituximab | – | ✓ |
| Targeted synthetic oral small-molecule DMARDs | |||
| PDE4 inhibitor | Apremilast | ✓ | – |
| Janus kinase inhibitor | Tofacitinib | ✓ | ✓ |
*Commonly used off-label.
†Discontinuation of systemic corticosteroids can cause serious psoriasis flare and dosing should be tapered instead of abruptly stopped.
‡Ciclosporin is not commonly used in RA.
CD, cluster of differentiation; DMARD, disease-modifying antirheumatic drug; FDA, Food and Drug Administration; IL, interleukin; PDE4, phosphodiesterase 4; PsA, psoriatic arthritis; RA, rheumatoid arthritis; TNF, tumour necrosis factor.